Second quarter 2018 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.
.2022-05-02-18-21-53.png)
We look forward to entering a new growth phase led by our increasing focus on Speciality Care and our leadership positions in Emerging Markets and Vaccines
Olivier Brandicourt
Chief Executive Officer